{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:47Z","timestamp":1786982687563,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-025-01055-5","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T01:29:13Z","timestamp":1767490153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["ANCA-negative pauci-immune crescentic glomerulonephritis associated with nivolumab in lung cancer"],"prefix":"10.1007","volume":"15","author":[{"given":"Riri","family":"Furuyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8422-7314","authenticated-orcid":false,"given":"Masahiro","family":"Eriguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Kamikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuki","family":"Beppu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikari","family":"Tasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Samejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Tsuruya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"1055_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","volume":"97","author":"MA Perazella","year":"2020","unstructured":"Perazella MA, Shirali AC. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? Kidney Int. 2020;97:62\u201374. https:\/\/doi.org\/10.1016\/j.kint.2019.07.022.","journal-title":"Kidney Int"},{"key":"1055_CR2","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90:638\u201347. https:\/\/doi.org\/10.1016\/j.kint.2016.04.008.","journal-title":"Kidney Int"},{"key":"1055_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","volume":"6","author":"A Kitchlu","year":"2021","unstructured":"Kitchlu A, Jhaveri KD, Wadhwani S, Deshpande P, Harel Z, Kishibe T, et al. A systematic review of immune checkpoint inhibitor-associated glomerular disease. Kidney Int Rep. 2021;6:66\u201377. https:\/\/doi.org\/10.1016\/j.ekir.2020.10.002.","journal-title":"Kidney Int Rep"},{"key":"1055_CR4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s13730-022-00750-x","volume":"12","author":"A Hoshina","year":"2023","unstructured":"Hoshina A, Endo S. Anti-glomerular basement membrane glomerulonephritis concurrent with membranous nephropathy and acute tubular interstitial nephritis in a lung cancer patient treated with pembrolizumab. CEN Case Rep. 2023;12:230\u20136. https:\/\/doi.org\/10.1007\/s13730-022-00750-x.","journal-title":"CEN Case Rep"},{"key":"1055_CR5","doi-asserted-by":"publisher","first-page":"e20464","DOI":"10.1097\/MD.0000000000020464","volume":"99","author":"K Tanabe","year":"2020","unstructured":"Tanabe K, Kanzaki H, Wada T, Nakashima Y, Sugiyama H, Okada H, Wada J. Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancer: A case report. Med (Baltim). 2020;99:e20464. https:\/\/doi.org\/10.1097\/MD.0000000000020464.","journal-title":"Med (Baltim)"},{"key":"1055_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","volume":"17","author":"K Jung","year":"2016","unstructured":"Jung K, Zeng X, Bilusic M. Nivolumab-associated acute glomerulonephritis: A case report and literature review. BMC Nephrol. 2016;17:188. https:\/\/doi.org\/10.1186\/s12882-016-0408-2.","journal-title":"BMC Nephrol"},{"key":"1055_CR7","doi-asserted-by":"publisher","first-page":"100682","DOI":"10.1016\/j.xkme.2023.100682","volume":"5","author":"N El Yamani","year":"2023","unstructured":"El Yamani N, Cote G, Riopel J, Marcoux N, Mac-Way F, Philibert D, Agharazii M. Pembrolizumab-induced anti-GBM glomerulonephritis: A case report. Kidney Med. 2023;5:100682. https:\/\/doi.org\/10.1016\/j.xkme.2023.100682.","journal-title":"Kidney Med"},{"key":"1055_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.lungcan.2018.05.015","volume":"122","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Tsuji K, Tamiya H, Shinohara T, Kuroda N, Takeuchi E. Goodpasture\u2019s disease in a patient with advanced lung cancer treated with nivolumab: an autopsy case report. Lung Cancer. 2018;122:22\u20134. https:\/\/doi.org\/10.1016\/j.lungcan.2018.05.015.","journal-title":"Lung Cancer"},{"key":"1055_CR9","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1016\/j.jtho.2017.03.011","volume":"12","author":"MH Heo","year":"2017","unstructured":"Heo MH, Kim HK, Lee H, Ahn MJ. Antineutrophil cytoplasmic antibody-associated rapid progressive glomerulonephritis after pembrolizumab treatment in thymic epithelial tumor: A case report. J Thorac Oncol. 2017;12:e103\u20135. https:\/\/doi.org\/10.1016\/j.jtho.2017.03.011.","journal-title":"J Thorac Oncol"},{"key":"1055_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1053\/j.ajkd.2019.04.016","volume":"74","author":"AJ Gallan","year":"2019","unstructured":"Gallan AJ, Alexander E, Reid P, Kutuby F, Chang A, Henriksen KJ. Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors. Am J Kidney Dis. 2019;74:853\u20136. https:\/\/doi.org\/10.1053\/j.ajkd.2019.04.016.","journal-title":"Am J Kidney Dis"},{"key":"1055_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12882-020-02044-9","volume":"21","author":"S Hultin","year":"2020","unstructured":"Hultin S, Nahar K, Menzies AM, Long GV, Fernando SL, Atkinson V, et al. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: A retrospective case series report. BMC Nephrol. 2020;21:391. https:\/\/doi.org\/10.1186\/s12882-020-02044-9.","journal-title":"BMC Nephrol"},{"key":"1055_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1159\/000518304","volume":"11","author":"R Laamech","year":"2021","unstructured":"Laamech R, Terrec F, Emprou C, Toffart AC, Pierret T, Naciri-Bennani H, et al. Efficacy of plasmapheresis in nivolumab-associated ANCA glomerulonephritis: A case report and pathophysiology discussion. Case Rep Nephrol Dial. 2021;11:376\u201383. https:\/\/doi.org\/10.1159\/000518304.","journal-title":"Case Rep Nephrol Dial"},{"key":"1055_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00428-020-02882-w","volume":"478","author":"M Uner","year":"2021","unstructured":"Uner M, Alhasson B, Obhrai J, Bagnasco SM. ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab. Virchows Arch. 2021;478:801\u20134. https:\/\/doi.org\/10.1007\/s00428-020-02882-w.","journal-title":"Virchows Arch"},{"key":"1055_CR14","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.ekir.2022.08.020","volume":"7","author":"T Tani","year":"2022","unstructured":"Tani T, Sugino K, Hashimoto K, Mii A, Kashiwagi T, Shimizu A, et al. Concomitant anti-GBM glomerulonephritis and acute interstitial nephritis following programmed death Receptor-1 Blockade with nivolumab. Kidney Int Rep. 2022;7:2317\u20138. https:\/\/doi.org\/10.1016\/j.ekir.2022.08.020.","journal-title":"Kidney Int Rep"},{"key":"1055_CR15","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.ekir.2022.04.089","volume":"7","author":"V Javaugue","year":"2022","unstructured":"Javaugue V, Watson MJ, Fervenza FC, Nasr SH. Atypical antiglomerular basement membrane nephritis following immune checkpoint inhibitor. Kidney Int Rep. 2022;7:1913\u20136. https:\/\/doi.org\/10.1016\/j.ekir.2022.04.089.","journal-title":"Kidney Int Rep"},{"key":"1055_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13256-021-02766-w","volume":"15","author":"P Kyriazis","year":"2021","unstructured":"Kyriazis P, Tiwary A, Freeman J, Landry D, Braden G. Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: A case report. J Med Case Rep. 2021;15:186. https:\/\/doi.org\/10.1186\/s13256-021-02766-w.","journal-title":"J Med Case Rep"},{"key":"1055_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ndtplus\/sfp177","volume":"3","author":"C Sammartino","year":"2010","unstructured":"Sammartino C, Goodman D, Flanagan G, Hill P. Anti-GBM disease following CTLA4 Blockade in a patient with metastatic melanoma. NDT Plus. 2010;3:135\u20137. https:\/\/doi.org\/10.1093\/ndtplus\/sfp177.","journal-title":"NDT Plus"},{"issue":"12","key":"1055_CR18","doi-asserted-by":"publisher","first-page":"sfae327","DOI":"10.1093\/ckj\/sfae327","volume":"17","author":"T Kuwabara","year":"2024","unstructured":"Kuwabara T, Miyasato Y, Kanki T, Mizumoto T, Matsubara T, Sawa N, et al. SUrvey of renal biopsy registry database and anticancer dRUg therapy in Japan (SUBARU-J study). Clin Kidney J. 2024;17(12):sfae327. https:\/\/doi.org\/10.1093\/ckj\/sfae327.","journal-title":"Clin Kidney J"},{"key":"1055_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1053\/j.ajkd.2019.03.433","volume":"74","author":"R Shingarev","year":"2019","unstructured":"Shingarev R, Glezerman IG. Kidney complications of immune checkpoint inhibitors: A review. Am J Kidney Dis. 2019;74:529\u201337. https:\/\/doi.org\/10.1053\/j.ajkd.2019.03.433.","journal-title":"Am J Kidney Dis"},{"key":"1055_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, et al. Adverse renal effects of immune checkpoint inhibitors: A narrative review. Am J Nephrol. 2017;45:160\u20139. https:\/\/doi.org\/10.1159\/000455014.","journal-title":"Am J Nephrol"},{"key":"1055_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3899\/jrheum.160885","volume":"44","author":"EE van Daalen","year":"2017","unstructured":"van Daalen EE, Rahmattulla C, Wolterbeek R, Bruijn JA, Bajema IM. Incidence of malignancy prior to antineutrophil cytoplasmic antibody-associated vasculitis compared to the general population. J Rheumatol. 2017;44:314\u20138. https:\/\/doi.org\/10.3899\/jrheum.160885.","journal-title":"J Rheumatol"},{"key":"1055_CR22","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ekir.2019.06.001","volume":"4","author":"C Cassol","year":"2019","unstructured":"Cassol C, Satoskar A, Lozanski G, Rovin B, Hebert L, Nadasdy T, Brodsky SV. Anti-PD-1 immunotherapy May induce interstitial nephritis with increased tubular epithelial expression of PD-L1. Kidney Int Rep. 2019;4:1152\u201360. https:\/\/doi.org\/10.1016\/j.ekir.2019.06.001.","journal-title":"Kidney Int Rep"},{"key":"1055_CR23","doi-asserted-by":"publisher","first-page":"624547","DOI":"10.3389\/fimmu.2020.624547","volume":"11","author":"S Hakroush","year":"2020","unstructured":"Hakroush S, Kopp SB, Tampe D, Gersmann AK, Korsten P, Zeisberg M, Tampe B. Variable expression of programmed cell death protein 1-ligand 1 in kidneys independent of immune checkpoint Inhibition. Front Immunol. 2020;11:624547. https:\/\/doi.org\/10.3389\/fimmu.2020.624547.","journal-title":"Front Immunol"},{"key":"1055_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12882-021-02257-6","volume":"22","author":"CS Curran","year":"2021","unstructured":"Curran CS, Kopp JB. PD-1 immunobiology in glomerulonephritis and renal cell carcinoma. BMC Nephrol. 2021;22:80. https:\/\/doi.org\/10.1186\/s12882-021-02257-6.","journal-title":"BMC Nephrol"},{"issue":"1","key":"1055_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12964-023-01084-6","volume":"21","author":"A Letian","year":"2023","unstructured":"Letian A, Lemma EY, Cavaliere P, Dephoure N, Altorki NK, McGraw TE. Proximity proteome mapping reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells. Cell Commun Signal. 2023;21(1):58. https:\/\/doi.org\/10.1186\/s12964-023-01084-6.","journal-title":"Cell Commun Signal"},{"issue":"6","key":"1055_CR26","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/1346-8138.17183","volume":"51","author":"K Oya","year":"2024","unstructured":"Oya K, Nakamura Y, Shen LT, Ishizuki S, Matsusaka S, Fujisawa Y, Soluble. PD-L1 predicts tumor response and immune-related adverse events in patients with advanced melanoma treated with anti-PD-1 antibodies. J Dermatol. 2024;51(6):807\u201315. https:\/\/doi.org\/10.1111\/1346-8138.17183.","journal-title":"J Dermatol"},{"key":"1055_CR27","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u2013126. https:\/\/doi.org\/10.1200\/JCO.21.01440.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1055_CR28","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1111\/j.1523-1755.2004.00632.x","volume":"65","author":"M Haas","year":"2004","unstructured":"Haas M, Eustace JA. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int. 2004;65(6):2145\u201352. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00632.x.","journal-title":"Kidney Int"},{"key":"1055_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/1756-185X.12836","volume":"19","author":"GA Ramirez","year":"2016","unstructured":"Ramirez GA, Mason JC, Tombetti E. Pauci-immune glomerulonephritis: the ANCA-negative side of the coin. Int J Rheum Dis. 2016;19:5\u20137. https:\/\/doi.org\/10.1111\/1756-185X.12836.","journal-title":"Int J Rheum Dis"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01055-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-025-01055-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01055-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T01:29:13Z","timestamp":1767490153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-025-01055-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1007\/s13730-025-01055-5","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have declared no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures in this study involving human participants were performed in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"10"}}